Mirum Pharmaceuticals price target raised to $58 from $45 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Mirum Pharmaceuticals to $58 from $45 and keeps a Buy rating on the shares after the FDA approved Livmarli for the treatment of cholestatic pruritus in patients five years of age and older with progressive familial intrahepatic cholestasis. This adds a second indication to the label following its initial approval for Alagille syndrome in September 2021, the analyst tells investors in a research note.